e/NMDA Receptor Modulators

Information
has gloss	eng: NMDA Receptor Modulators (glutamate antagonists) are a new form of antipsychotic that are in Phase II FDA study. The first compound studied was glycine which was hypothesized by Dr. Daniel Javitt "www.esi-topics.com/schizophrenia/interviews/Dr-Daniel-Javitt.html" after observation that people with PCP induced psychosis were lacking in glutamate transmission. In giving glycine to people with PCP induced psychosis a recovery rate was noted. From there, it was hypothesized that people with psychosis from schizophrenia would benefit from increased glutamate transmission and glycine was added with strong recovery rates noted especially in the area of negative and cognitive symptoms. Glycine, however, sporadic results aside remains an adjunct antipsychotic and an unworkable compound. However, the Eli Lilly study drug LY2140023 is being studied as a primary antipsychotic and is showing strong recovery rates, especially in the area of negative and cognitive symptoms of schizophrenia.
lexicalization	eng: NMDA Receptor Modulators
instance of	(noun) tranquilizer used to treat psychotic conditions when a calming effect is desired neuroleptic agent, antipsychotic drug, major tranquilizer, neuroleptic drug, major tranquilliser, antipsychotic agent, major tranquillizer, antipsychotic, neuroleptic